Analysis Tools
immune system
| N |
• spleens and Peyer's patches are normal in size, and show germinal centers of normal morphologies; numbers of IgM+, B220+ B cells in peripheral compartments are normal
|
|
• resting B cells have lower surface expression of IgM
|
|
• mutants exhibit a severe CSR defect; the defect slightly affects IgM and IgG1 levels, whereas IgG2b and IgG3 are significantly affected both in vivo and in vitro, with IgG2a amd IgE classes are moderately affected
• IgA serum levels are close to normal, but germline transcription of the alpha gene and IgA secretion are decreased with LPS + TGF beta stimulation
|
|
• LPS + TGF beta-stimulated IgA production in vitro is lowered ~3-fold; in vivo, serum levels are 15-fold lower than wild-type
|
|
• LPS + Il-4-stimulated IgE production is decreased ~10-fold compared to wild-type; in most experiments, levels are below detection limits; in vivo, levels are reduced at least 300-fold to almost undetectable levels
|
|
• IgG1 production is decreased ~4-fold in vitro; in vivo, levels are decreased 15-fold relative to wild-type
|
|
• LPS + IFN gamma-stimulated IgG2a secretion in vitro is decreased ~10-fold; in vivo serum levels of IgG2a are decreased ~4-fold
|
|
• LPS-stimulated B cells secrete 15-fold less IgG2b than wild-type cells in vitro; in vivo, IgG2b levels are decreased 5-fold
|
|
• LPS-stimulated B cells secrete 100-fold less IgG3 than wild-type cells in vitro; in vivo, IgG3 is decreased 50-fold
|
|
• in vivo, serum levels are decreased 4-fold relative to wild-type
|
hematopoietic system
|
• resting B cells have lower surface expression of IgM
|
|
• mutants exhibit a severe CSR defect; the defect slightly affects IgM and IgG1 levels, whereas IgG2b and IgG3 are significantly affected both in vivo and in vitro, with IgG2a amd IgE classes are moderately affected
• IgA serum levels are close to normal, but germline transcription of the alpha gene and IgA secretion are decreased with LPS + TGF beta stimulation
|
|
• LPS + TGF beta-stimulated IgA production in vitro is lowered ~3-fold; in vivo, serum levels are 15-fold lower than wild-type
|
|
• LPS + Il-4-stimulated IgE production is decreased ~10-fold compared to wild-type; in most experiments, levels are below detection limits; in vivo, levels are reduced at least 300-fold to almost undetectable levels
|
|
• IgG1 production is decreased ~4-fold in vitro; in vivo, levels are decreased 15-fold relative to wild-type
|
|
• LPS + IFN gamma-stimulated IgG2a secretion in vitro is decreased ~10-fold; in vivo serum levels of IgG2a are decreased ~4-fold
|
|
• LPS-stimulated B cells secrete 15-fold less IgG2b than wild-type cells in vitro; in vivo, IgG2b levels are decreased 5-fold
|
|
• LPS-stimulated B cells secrete 100-fold less IgG3 than wild-type cells in vitro; in vivo, IgG3 is decreased 50-fold
|
|
• in vivo, serum levels are decreased 4-fold relative to wild-type
|
